DDInter1853 DDInter1658
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Tretinoin {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Tretinoin {u} (Compound) binds {v} (Gene) CYP1A1
Tretinoin {u} (Compound) upregulates {v} (Gene) DHRS3
Tretinoin {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Tretinoin {u} (Compound) downregulates {v} (Gene) ATP6V1D
Tretinoin {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Tretinoin (Compound) resembles Isotretinoin (Compound)
Tretinoin (Compound) treats peripheral nervous system neoplasm (Disease)
Tretinoin (Compound) binds CYP1A1 (Gene)
Tretinoin (Compound) upregulates DHRS3 (Gene)
Tretinoin (Compound) is included by Retinoids (Pharmacologic Class)
Tretinoin (Compound) downregulates ATP6V1D (Gene)
Tretinoin (Compound) causes Agranulocytosis (Side Effect)